Advertisement · 728 × 90
#
Hashtag
#Bladder_Cancer
Advertisement · 728 × 90
Preview
Innovative Bladder Cancer Trials Presented at EAU 2026 Congress for Enhanced Patient Care At the EAU 2026 Congress, Photocure presented innovative trials focusing on personalized treatments for bladder cancer, enhancing patient outcomes through advanced methodologies.

Innovative Bladder Cancer Trials Presented at EAU 2026 Congress for Enhanced Patient Care #Norway #Oslo #Bladder_Cancer #Photocure #Hexvix

0 0 0 0
Preview
Photocure's Innovative Trials at EAU 2026 Focus on Tailored Bladder Cancer Treatments Photocure ASA showcases critical trials at EAU 2026 aimed at enhancing personalized care pathways for bladder cancer patients, emphasizing innovative solutions.

Photocure's Innovative Trials at EAU 2026 Focus on Tailored Bladder Cancer Treatments #Norway #Oslo #Bladder_Cancer #Photocure #EAU_2026

0 0 0 0
Preview
Promising Phase 1 Results for Erda-iDRS in Bladder Cancer Patients Show High Response Rate Johnson & Johnson announced favorable findings from their Phase 1 study of Erda-iDRS, indicating an efficient treatment for non-muscle-invasive bladder cancer with an 89% response rate.

Promising Phase 1 Results for Erda-iDRS in Bladder Cancer Patients Show High Response Rate #United_States #Johnson_&_Johnson #Raritan #Bladder_Cancer #Erda-iDRS

0 0 0 0
Preview
ImmVira Presents Promising MVR-T3011 Data for Bladder Cancer at ASCO GU 2026 At the ASCO GU 2026 Conference, ImmVira showcased early results from a clinical trial of MVR-T3011 for BCG-naïve bladder cancer patients, signaling potential expansion in treatment options.

ImmVira Presents Promising MVR-T3011 Data for Bladder Cancer at ASCO GU 2026 #China #Suzhou #Bladder_Cancer #ImmVira #MVR-T3011

1 0 0 0
Preview
CorePlus and AIxMED Revolutionize Bladder Cancer Detection with AI-Driven Technology CorePlus and AIxMED unveil an innovative AI-powered solution, AIxURO, enhancing bladder cancer diagnosis efficiency and accuracy, revolutionizing patient care.

CorePlus and AIxMED Revolutionize Bladder Cancer Detection with AI-Driven Technology #United_States #San_Juan #Bladder_Cancer #CorePlus #AIxMed

0 0 0 0
Preview
Innovative Cancer Treatment: PADCEV Plus Keytruda Boosts Survival in Bladder Cancer Patients The combination of PADCEV and Keytruda demonstrates significant improvements in survival rates for patients with muscle-invasive bladder cancer. This marks a potential new standard of care.

Innovative Cancer Treatment: PADCEV Plus Keytruda Boosts Survival in Bladder Cancer Patients #Japan #Tokyo #KEYTRUDA #PADCEV #Bladder_Cancer

0 0 0 0
Preview
Blue Light Cystoscopy's Economic Advantage Explored in BRAVO Study Findings The BRAVO study reveals that while blue light cystoscopy incurs higher initial costs, lower recurrence rates lead to overall cost neutrality in bladder cancer care.

Blue Light Cystoscopy's Economic Advantage Explored in BRAVO Study Findings #Norway #Oslo #Bladder_Cancer #Photocure_ASA #Blue_Light_Cystoscopy

0 0 0 0
Preview
The BRAVO Study: Cost Neutrality in Cystoscopy for Bladder Cancer Patients Presented at SUO 2025 The latest findings from the BRAVO study showcase the cost neutrality of blue light versus white light cystoscopy in treating bladder cancer, emphasizing real-world savings.

The BRAVO Study: Cost Neutrality in Cystoscopy for Bladder Cancer Patients Presented at SUO 2025 #Norway #Oslo #Bladder_Cancer #Photocure_ASA #BRAVO_Study

0 0 0 0
Preview
Johnson & Johnson's INLEXZO™ Shows Promising Results for Treating High-Risk Bladder Cancer Johnson & Johnson's recent SunRISe-1 study indicates that INLEXZO™ significantly boosts disease-free survival rates in high-risk bladder cancer patients unresponsive to BCG treatment.

Johnson & Johnson's INLEXZO™ Shows Promising Results for Treating High-Risk Bladder Cancer #United_States #Johnson_&_Johnson #Raritan #Bladder_Cancer #INLEXZO

0 0 0 0
Preview
New Study Highlights Economic Benefits of Blue Light Cystoscopy in Managing Bladder Cancer Across Europe A recent study reveals that the use of blue light cystoscopy (BLC) offers significant clinical and economic advantages for non-muscle-invasive bladder cancer in four European countries.

New Study Highlights Economic Benefits of Blue Light Cystoscopy in Managing Bladder Cancer Across Europe #Norway #Oslo #Bladder_Cancer #Photocure #BLC

0 0 0 0
Preview
Photocure and Intelligent Scopes Unveil AI-Driven Solutions for Enhanced Bladder Cancer Diagnosis Photocure ASA partners with Intelligent Scopes Corporation to develop innovative AI software for improving bladder cancer detection through blue light cystoscopy.

Photocure and Intelligent Scopes Unveil AI-Driven Solutions for Enhanced Bladder Cancer Diagnosis #Norway #Oslo #Bladder_Cancer #Photocure #Intelligent_Scopes

0 0 0 0
Preview
FDA Approves INLEXZO™: A Breakthrough in Bladder Cancer Treatment Options The FDA has approved INLEXZO™, a revolutionary treatment for certain bladder cancers, offering hope to patients unresponsive to traditional therapies.

FDA Approves INLEXZO™: A Breakthrough in Bladder Cancer Treatment Options #United_States #Johnson_&_Johnson #Bladder_Cancer #INLEXZO#RARITAN,_N.J.

0 0 0 0
Preview
Hamlet BioPharma Completes Alpha1H Phase II Study in Bladder Cancer Hamlet BioPharma announces the successful completion of the Phase II clinical study for Alpha1H, a promising treatment for non-muscle invasive bladder cancer which shows significant efficacy and safety.

Hamlet BioPharma Completes Alpha1H Phase II Study in Bladder Cancer #Sweden #Lund #Bladder_Cancer #Alpha1H #Hamlet_BioPharma

0 0 0 0
Preview
BCAN Extends Support to Deion Sanders Following His Bladder Cancer Diagnosis The Bladder Cancer Advocacy Network offers their heartfelt support to Deion Sanders after his diagnosis of bladder cancer, emphasizing the importance of awareness.

BCAN Extends Support to Deion Sanders Following His Bladder Cancer Diagnosis #United_States #Bethesda #Deion_Sanders #Bladder_Cancer #BCAN

0 0 0 0
Preview
Understanding Bladder Cancer: Symptoms, Risk Factors, and Importance of Early Diagnosis Bladder cancer is more common than many realize. Learn about symptoms, risk factors, and the importance of consulting a specialist if you notice any warning signs.

Understanding Bladder Cancer: Symptoms, Risk Factors, and Importance of Early Diagnosis #United_States #Aurora #Bladder_Cancer #University_of_Colorado #Urologic_Oncology

0 0 0 0
Preview
Johnson & Johnson's TAR-200: Pioneering the Future of Bladder Cancer Treatment with FDA Review Johnson & Johnson's TAR-200 gains U.S. FDA Priority Review for treating high-risk bladder cancer, transforming patient care dynamics.

Johnson & Johnson's TAR-200: Pioneering the Future of Bladder Cancer Treatment with FDA Review #USA #New_Jersey #Johnson_&_Johnson #Bladder_Cancer #TAR-200

0 0 0 0
Preview
BCAN Announces $1 Million Grant to Propel Bladder Cancer Research Forward The Bladder Cancer Advocacy Network unveils a significant Funding Continuity Grant of up to $1 million, supporting critical bladder cancer research initiatives.

BCAN Announces $1 Million Grant to Propel Bladder Cancer Research Forward #United_States #Bethesda #Bladder_Cancer #BCAN #Research_Grant

0 0 0 0
Preview
TOBY's Breakthrough AI-Powered Urine Test for Bladder Cancer Gains FDA Approval TOBY, Inc. has achieved FDA Breakthrough Designation for its innovative urine test to detect bladder cancer early, revolutionizing cancer screening.

TOBY's Breakthrough AI-Powered Urine Test for Bladder Cancer Gains FDA Approval #United_States #Boston #Bladder_Cancer #TOBY_Inc #AI_Urine_Test

0 0 0 0
Preview
Tyra Biosciences Begins Phase 2 Trial of TYRA-300 for Bladder Cancer Tyra Biosciences has initiated the Phase 2 SURF302 clinical trial of TYRA-300, an innovative treatment for low-grade, intermediate-risk non-muscle invasive bladder cancer. Initial data is expected in 2026.

Tyra Biosciences Begins Phase 2 Trial of TYRA-300 for Bladder Cancer #United_States #Carlsbad #Tyra_Biosciences #TYRA-300 #Bladder_Cancer

0 0 0 0
Preview
ImmVira Begins Phase II Trial of Oncolytic Therapy for Bladder Cancer ImmVira has launched its first patient dosing in a Phase II trial assessing MVR-T3011 for high-risk bladder cancer patients unresponsive to BCG treatment.

ImmVira Begins Phase II Trial of Oncolytic Therapy for Bladder Cancer #China #Suzhou #Bladder_Cancer #ImmVira #MVR-T3011

0 0 0 0
Preview
Photocure ASA Reports Strong Growth in Q1 2025 with Boost in Bladder Cancer Product Sales Photocure ASA has reported impressive growth for Q1 2025, with revenues of NOK 125.3 million and a focus on expanding bladder cancer treatments using innovative technologies.

Photocure ASA Reports Strong Growth in Q1 2025 with Boost in Bladder Cancer Product Sales #Norway #Oslo #Bladder_Cancer #Photocure #Hexvix

0 0 0 0
Preview
Photocure ASA Reports Strong Financial Results for Q1 2025 with Continued Growth in Bladder Cancer Treatments Photocure ASA has announced a revenue increase for Hexvix®/Cysview® in Q1 2025. With strong performance in Europe and North America, growth looks promising for the year ahead.

Photocure ASA Reports Strong Financial Results for Q1 2025 with Continued Growth in Bladder Cancer Treatments #Norway #Oslo #Bladder_Cancer #Photocure_ASA #Hexvix

0 0 0 0
Preview
Bladder Cancer Awareness Month: The Time to Act Is Now for Detection and Awareness As Bladder Cancer Awareness Month begins, the call for recognition and prevention becomes urgent. BCAN urges everyone to spread awareness.

Bladder Cancer Awareness Month: The Time to Act Is Now for Detection and Awareness #United_States #Bethesda #Bladder_Cancer #BCAN #Awareness_Month

0 0 0 0
Preview
AUA2025: Advances in Bladder Cancer Management with Blue Light Cystoscopy At AUA2025, Photocure ASA showcased Blue Light Cystoscopy's significant role in improving bladder cancer management and patient decision-making.

AUA2025: Advances in Bladder Cancer Management with Blue Light Cystoscopy #Las_Vegas #Norway #Bladder_Cancer #Photocure_ASA #Blue_Light_Cystoscopy

0 0 0 0
Preview
Johnson & Johnson's TAR-200 Monotherapy Shows Promising Long-Term Efficacy in Bladder Cancer Treatment New data from Johnson & Johnson shows that TAR-200 monotherapy achieves over 82% complete response in certain bladder cancer patients, with significant long-term benefits.

Johnson & Johnson's TAR-200 Monotherapy Shows Promising Long-Term Efficacy in Bladder Cancer Treatment #USA #Johnson_&_Johnson #Las_Vegas #Bladder_Cancer #TAR-200

0 0 0 0
Preview
Johnson & Johnson Presents Groundbreaking Findings on Bladder Cancer Treatment at AUA 2025 Johnson & Johnson reveals new and promising data regarding TAR-200, a novel treatment for bladder cancer, at AUA 2025 in Las Vegas.

Johnson & Johnson Presents Groundbreaking Findings on Bladder Cancer Treatment at AUA 2025 #USA #Johnson_&_Johnson #Las_Vegas #Bladder_Cancer #TAR-200

0 0 0 0
Preview
BCAN Partners with Ferring and Astellas/Pfizer for Bladder Cancer Walks in 2025 The Bladder Cancer Advocacy Network has partnered with Ferring Pharmaceuticals and Astellas/Pfizer as sponsors for the 2025 Walks to End Bladder Cancer, boosting awareness and support.

BCAN Partners with Ferring and Astellas/Pfizer for Bladder Cancer Walks in 2025 #United_States #Bethesda #Bladder_Cancer #Ferring_Pharmaceuticals #Astellas_Pfizer

0 0 0 0
Preview
Photocure Embraces Change with the Appointment of Jane Healy as New VP and GM for EMEA Photocure has appointed Jane Healy as Vice President and General Manager for the EMEA region. Her extensive background in medical devices aims to enhance growth in uro-oncology.

Photocure Embraces Change with the Appointment of Jane Healy as New VP and GM for EMEA #Norway #Oslo #Bladder_Cancer #Photocure #Jane_Healy

0 0 0 0
Preview
Jane Healy Takes on Leadership Role at Photocure as EMEA General Manager Photocure ASA welcomes Jane Healy as the new Vice President and General Manager for EMEA, bringing extensive medical device expertise to the role.

Jane Healy Takes on Leadership Role at Photocure as EMEA General Manager #Norway #Oslo #Bladder_Cancer #Photocure #Jane_Healy

0 0 0 0
Preview
Ractigen's RAG-01 Demonstrates Early Efficacy in Bladder Cancer Trial Presented at EAU 2025 Ractigen Therapeutics revealed promising results from its Phase I trial for RAG-01, a new treatment for non-muscle invasive bladder cancer, showcasing a 66.7% response rate.

Ractigen's RAG-01 Demonstrates Early Efficacy in Bladder Cancer Trial Presented at EAU 2025 #China #Bladder_Cancer #Ractigen #RAG-01 #Nantong

0 0 0 0